Home » Stocks » QURE

uniQure N.V. (QURE)

Stock Price: $39.26 USD 0.68 (1.76%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $39.38 +0.12 (0.31%) Jan 22, 7:32 PM
Market Cap 1.75B
Revenue (ttm) 6.05M
Net Income (ttm) -165.75M
Shares Out 44.47M
EPS (ttm) -3.75
PE Ratio n/a
Forward PE 27.93
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $39.26
Previous Close $38.58
Change ($) 0.68
Change (%) 1.76%
Day's Open 38.26
Day's Range 37.88 - 39.41
Day's Volume 301,292
52-Week Range 35.35 - 67.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to ...

Investors Business Daily - 1 month ago

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Other stocks mentioned: EDIT, NTLA
The Motley Fool - 1 month ago

A clinical hold is weighing on the biotech's shares today.

24/7 Wall Street - 1 month ago

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

Other stocks mentioned: ACAD, NBIX, VRTX, ZGNX
Benzinga - 1 month ago

Uniqure NV (NASDAQ: QURE) shares are moving sharply to the downside after the gene therapy company announced a setback to its clinical study. What Happened: Lexington, Massachusetts-based uniQ...

GlobeNewsWire - 1 month ago

Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET

Zacks Investment Research - 1 month ago

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Other stocks mentioned: BMRN, DCPH, RGNX
GlobeNewsWire - 1 month ago

~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~

24/7 Wall Street - 1 month ago

The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.

Other stocks mentioned: ACAD, CVS, HR
GlobeNewsWire - 1 month ago

LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

GlobeNewsWire - 1 month ago

~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~

Benzinga - 2 months ago

UniQure NV (NASDAQ: QURE) shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, Massachusetts-based company announce...

Investors Business Daily - 2 months ago

Shares of QURE stock bounded higher Thursday after Uniqure reported promising results for its hemophilia B gene therapy. The company says the drug improved clotting protein at 26 weeks.

GlobeNewsWire - 2 months ago

~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~

GlobeNewsWire - 2 months ago

LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medica...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients w...

Zacks Investment Research - 2 months ago

uniQure (QURE) delivered earnings and revenue surprises of -171.18% and -98.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~

Insider Monkey - 2 months ago

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry exp...

Other stocks mentioned: BPMC, ANAB, DRNA, SPRO
Insider Monkey - 2 months ago

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...

Zacks Investment Research - 3 months ago

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medica...

Forbes - 3 months ago

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interes...

Other stocks mentioned: RGNX, SRPT, VYGR
GlobeNewsWire - 3 months ago

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medic...

GlobeNewsWire - 3 months ago

~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment; No Significant Safety Concerns Observed to Prevent Further Dosing ~ ~ Independent Data Safety Monitoring...

GlobeNewsWire - 4 months ago

LEXINGTON, Mass. and AMSTERDAM, Sept. 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe med...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to uniQure (QURE) stock based on the movements in the options market lately.

GlobeNewsWire - 4 months ago

Announces Planned Departure of Sander van Deventer and Transition of Robert Gut Who is Expected to Remain on the Board of Directors Announces Planned Departure of Sander van Deventer and Trans...

Seeking Alpha - 5 months ago

We take a quick look at uniQure today.

Zacks Investment Research - 5 months ago

uniQure (QURE) delivered earnings and revenue surprises of -100.00% and -91.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~

Zacks Investment Research - 5 months ago

UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 6 months ago

Agreement licenses the rights for a promising hemophilia B gene therapy.

Market Watch - 6 months ago

Shares of UniQure QURE, -7.13% tumbled 17% in premarket trading on Thursday, the day after it announced that CSL Behring CSL, +0.56% would acquire exclusive commercialization rights to its gen...

Investors Business Daily - 7 months ago

Biotech company Uniqure inked a $2 billion licensing deal for its hemophilia B gene therapy late Wednesday. But shares of QURE stock collapsed in response in after-hours trading.

GlobeNewsWire - 7 months ago

~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~

Seeking Alpha - 7 months ago

Did Sanofi Free Up Cash To Acquire uniQure?

Other stocks mentioned: SNY
GlobeNewsWire - 7 months ago

~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~ ~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~

GlobeNewsWire - 7 months ago

~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~

GlobeNewsWire - 7 months ago

~ Virtual Meeting Only by Live Audio Webcast – No Physical Meeting Location ~

Investors Business Daily - 7 months ago

A Relative Strength Rating upgrade for Uniqure N.V. shows improving technical performance.

Zacks Investment Research - 7 months ago

uniQure N.V. (QURE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Forbes - 8 months ago

Companies that have been able to deliver compelling results have been acquired by big pharma companies (for instance, Spark Therapeutics was acquired by Roche), while others have underperforme...

Other stocks mentioned: RGNX, SRPT
Zacks Investment Research - 8 months ago

uniQure (QURE) delivered earnings and revenue surprises of 26.74% and -94.09%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ ~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~

GlobeNewsWire - 9 months ago

Provides Update on Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease and Response to COVID-19 Pandemic Provides Update on Phase I/II Clinical Trial of AMT-130 in Huntington’s Disea...

Zacks Investment Research - 10 months ago

uniQure (QURE) delivered earnings and revenue surprises of -24.36% and 49.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 10 months ago

~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure’s Product Portfolio ~

Zacks Investment Research - 10 months ago

uniQure (QURE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

About QURE

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an on... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2007
CEO
Matthew Craig Kapusta
Employees
248
Stock Exchange
NASDAQ
Ticker Symbol
QURE
Full Company Profile

Financial Performance

In 2019, uniQure's revenue was $7.28 million, a decrease of -35.48% compared to the previous year's $11.28 million. Losses were -$124.20 million, 49.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for uniQure stock is "Strong Buy." The 12-month stock price forecast is 69.26, which is an increase of 76.41% from the latest price.

Price Target
$69.26
(76.41% upside)
Analyst Consensus: Strong Buy